Physician profile
Kyle B Stephens
NPI 1205204518
$2,330.01
in general payments reported to CMS, 2019-2025
25 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $14.05 · 2021: $103 · 2022: $310 · 2023: $390 · 2024: $608 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $426.59 | 2023-2025 | Evenity, Repatha, Repatha |
| Novo Nordisk INC | $212.13 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $189.99 | 2024-2025 | Sapien 3 Ultra Resilia |
| Otsuka America Pharmaceutical, INC. | $164.53 | 2023-2024 | Rexulti, Abilify Maintena |
| Neotract INC. | $160.11 | 2019 | |
| Abbvie INC. | $149.65 | 2021-2025 | Vraylar |
| Teleflex LLC | $147.66 | 2022-2024 | Urolift |
| Lilly USA, LLC | $143.93 | 2022-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $114.28 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $104.74 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $102.03 | 2022-2025 | Shingrix, Arexvy |
| Almatica Pharma LLC | $91.44 | 2021-2025 | Loreev Xr, Sertraline Hcl, Gralise |
| Janssen Pharmaceuticals, INC | $44.95 | 2021-2022 | |
| Phadia US INC. | $36.87 | 2021-2022 | |
| Exact Sciences Corporation | $34.84 | 2023 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.03 | 2021 | |
| Sanofi Pasteur INC. | $23.81 | 2023 | |
| Eisai INC. | $22.26 | 2025 | |
| Boston Scientific Corporation | $20.73 | 2023 | |
| Coloplast Corp | $19.96 | 2024 | |
| Organon LLC | $19.93 | 2022 | |
| Cranial Technologies, INC | $19.05 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $18.25 | 2024 | Varivax, Gardasil 9, Gardasil |
| Microtransponder, INC. | $17.41 | 2023 | |
| Pfizer INC. | $15.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.